The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Inhaled Steroids in Asthma Therapy: An Update

흡입 스테로이드제제의 Update

  • Jang, An-Soo (Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University School of Medicine)
  • 장안수 (순천향대학교 의과대학 내과학교실)
  • Published : 2011.02.01
⟨ Previous Next ⟩

Abstract

Asthma is a chronic inflammatory disease of airways in which many cells and cellular elements play a role. The chronic airway inflammation is associated with airway hyper-responsiveness, causing recurring episodes of wheezing, breathlessness, chest tightness, and coughing. The goal of asthma treatment, to achieve and maintain clinical control, can be reached in most patients with pharmacological treatment. Inhaled glucocorticoids are a very effective treatment for asthma. This review provides an update on inhaled glucocorticoids therapy and recent findings.

Keywords

References

  1. National Institutes of Health, National Heart, Lung, and Blood Institute. National asthma education and prevention program: global strategy for asthma management and prevention. Global initiative for asthma report. 2009. Available from www.ginasthma.org.
  2. Lee YM, Park JS, Hwang JH, et al. High-resolution CT findings in patients with near-fatal asthma: comparison of patients with mild-to-severe asthma and normal control subjects and changes in airway abnormalities following steroid treatment. Chest 2004;126:1840-1848. https://doi.org/10.1378/chest.126.6.1840
  3. Chetta A, Foresi A, Del Donno M, Bertorelli G, Pesci A, Olivieri D. Airways remodeling is a distinctive feature of asthma and is related to severity of disease. Chest 1997;111:852-857. https://doi.org/10.1378/chest.111.4.852
  4. Reed CE. The natural history of asthma in adults: the problem of irreversibility. J Allergy Clin Immunol 1999;103:539-547. https://doi.org/10.1016/S0091-6749(99)70221-6
  5. Ten Hacken NH, Postma DS, Timens W. Airway remodeling and long-term decline in lung function in asthma. Curr Opin Pulm Med 2003;9:9-14. https://doi.org/10.1097/00063198-200301000-00002
  6. Barnes PJ. Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol 1998;102:531-538. https://doi.org/10.1016/S0091-6749(98)70268-4
  7. 2007 한국 성인천식의 치료지침. 천식 및 알레르기학회 Available from: http://www.allergy.or.kr
  8. Barnes PJ. Corticosteroids: the drugs to beat. Eur J Pharmacol 2006;533:2-14. https://doi.org/10.1016/j.ejphar.2005.12.052
  9. Kelly HW. Comparison of inhaled corticosteroids: an update. Ann Pharmacother 2009;43:519-527. https://doi.org/10.1345/aph.1L546
  10. Deeks ED, Perry CM. Ciclesonide: a review of its use in the management of asthma. Drugs 2008;68:1741-1770. https://doi.org/10.2165/00003495-200868120-00010
  11. Derom E, Van De Velde V, Marissens S, Engelstätter R, Vincken W, Pauwels R. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5'monophosphate in asthmatic patients. Pulm Pharmacol Ther 2005;18:328-336. https://doi.org/10.1016/j.pupt.2005.01.004
  12. Lee DK, Fardon TC, Bates CE, Haggart K, McFarlane LC, Lipworth BJ. Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma. Chest 2005;127:851-860. https://doi.org/10.1378/chest.127.3.851
  13. Pedersen S, Garcia Garcia ML, Manjra A, Theron I, Engelstätter R. A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatr Pulmonol 2006;41:954-961. https://doi.org/10.1002/ppul.20474
  14. O'Connor B, Bonnaud G, Haahtela T, et al. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Ann Allergy Asthma Immunol 2001;86:397-404. https://doi.org/10.1016/S1081-1206(10)62485-4
  15. Sharpe M, Jarvis B. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. Drugs 2001;61:1325-1350. https://doi.org/10.2165/00003495-200161090-00011
  16. Kelly HW. Comparison of inhaled corticosteroids. Ann Pharmacother 1998;32:220-232. https://doi.org/10.1345/aph.17014
  17. Winkler J, Hochhaus G, Derendorf H. How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc 2004;1:356-363. https://doi.org/10.1513/pats.200403-025MS
  18. Kelly HW. Pharmaceutical characteristics that influence the clinical efficacy of inhaled corticosteroids. Ann Allergy Asthma Immunol 2003;91:326-334. https://doi.org/10.1016/S1081-1206(10)61677-8
  19. Hubner M, Hochhaus G, Derendorf H. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am 2005;25:469-488. https://doi.org/10.1016/j.iac.2005.05.004
  20. Rossi GA, Cerasoli F, Cazzola M. Safety of inhaled corticosteroids: room for improvement. Pulm Pharmacol Ther 2007;20:23-35. https://doi.org/10.1016/j.pupt.2005.10.008
  21. Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 2006;28:1042-1050. https://doi.org/10.1183/09031936.00074905
  22. Fanta CH. Asthma. N Engl J Med 2009;360:1002-1014. https://doi.org/10.1056/NEJMra0804579
  23. Rodrigo GJ. Rapid effects of inhaled corticosteroids in acute asthma: an evidence-based evaluation. Chest 2006;130:1301-1311. https://doi.org/10.1378/chest.130.5.1301
  24. Busse WW, Banks-Schlegel S, Wenzel SE. Pathophysiology of severe asthma. J Allergy Clin Immunol 2000;106:1033-1042. https://doi.org/10.1067/mai.2000.111307
  25. Jang AS, Lee JH, Park SW, Park JS, Kim DJ, Park CS. Risk factors related to fixed airway obstruction in patients with asthma after antiasthma treatment. Ann Allergy Asthma Immunol 2007;99:408-412. https://doi.org/10.1016/S1081-1206(10)60564-9
  26. Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008;372:1073-1087. https://doi.org/10.1016/S0140-6736(08)61449-X